Safety and immunogenicity of 2010–2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12–59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: A PHAC/CIHR Influenza Research Network (PCIRN) study

This publication has 10 references indexed in Scilit:

• H1N1 Antibody Persistence 1 Year After Immunization With an Adjuvanted or Whole-Virion Pandemic Vaccine and Immunogenicity and Reactogenicity of Subsequent Seasonal Influenza Vaccine: A Multicenter Follow-on Study
  Clinical Infectious Diseases, 2012
• Evaluation of Adjuvanted Pandemic H1N12009 Influenza Vaccine After One and Two Doses in Young Children
  The Pediatric Infectious Disease Journal, 2011
• Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta‐analysis
  Influenza and Other Respiratory Viruses, 2011
• Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009
  BMJ, 2011
• Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6–35 months
  Vaccine, 2010
• Protective effect of single‐dose adjuvanted pandemic influenza vaccine in children
  Influenza and Other Respiratory Viruses, 2010
• Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study
  BMJ, 2010
• Influenza Vaccine Immunogenicity in 6- to 23-Month-Old Children: Are Identical Antigens Necessary for Priming?
  Pediatrics, 2006
• A Comparison of 2 Influenza Vaccine Schedules in 6- to 23-Month-Old Children
  Pediatrics, 2005
• Effectiveness of Inactivated Influenza Vaccine in Preventing Acute Otitis Media in Young Children
  JAMA, 2003